Capricor, Inc. Appoints Anthony Davies, Ph.D., Chief Technology Officer
LOS ANGELES -- March 7, 2013
Capricor, Inc., a privately held biotechnology company whose cardiac-derived
stem cells (CDCs) are being studied as a potentially novel treatment to repair
the heart following large heart attacks, announced today that it has appointed
Anthony Davies, Ph.D., to the newly created position of Chief Technology
Officer. Dr. Davies will be responsible for manufacturing, development and
expansion of Capricor’s cell-based therapeutic portfolio and will report to
Linda Marbán, Ph.D., Chief Executive Officer of Capricor.
Dr. Marbán said, "Dr. Davies is a 20-year veteran of the biotech industry, 15
years of which have been in cell and gene therapy. He brings with him an
impressive track record in manufacturing, operational management and
commercial development, most recently as Vice President, Product Development
for Geron Corporation’s cell therapy programs. He is an important addition to
Capricor’s management team as Capricor proceeds with the ongoing enrollment of
ALLSTAR, the Phase I/II study of our lead product candidate, cardiac-stem cell
Prior to joining Geron Corporation, Dr. Davies had a successful career in
process development and manufacturing at notable companies such as
Serologicals Corporation, Velico Medical, Inc. (formerly ZymeQuest, Inc.) and
Onyx Pharmaceuticals, Inc. While at Onyx, Dr. Davies was part of the
development team for Nexavar®, a kinase inhibitor with nearly a billion
dollars in worldwide sales.
Commenting on his appointment, Dr. Davies said, "Having spent a significant
part of my career in cell therapy, I view Capricor as the most exciting
company in the arena. Capricor’s cardiac stem cell therapy is highly
differentiated and addresses the huge unmet need of heart disease. I look
forward to working with Dr. Marbán and the Capricor team to bring CAP-1002 to
Dr. Davies received a MA in Biochemistry from the University of Cambridge and
a Ph.D. from the University of Birmingham. He conducted postdoctoral research
at the Institute of Virology at Oxford and the University of California, San
CAP-1002, Capricor's lead product candidate, is a proprietary allogeneic adult
stem cell therapy for the treatment of cardiac damage resulting from a heart
attack. The product is derived from donor heart tissue. The cells are expanded
in the laboratory using a specialized process and then introduced directly
into a patient’s heart via infusion into a coronary artery using standard
cardiac catheterization techniques.
CAP-1002 is currently not an approved product and is strictly for
About Capricor, Inc.
Los Angeles-based Capricor is a privately held biotechnology company that aims
to create powerful, yet easy-to-administer cardiac stem cell treatments to
regenerate damaged heart muscle and improve heart function for patients having
suffered a heart attack. Using proprietary technology, Capricor is working to
develop and commercialize therapies that utilize stem cells that are
indigenous to the heart itself. Where most other organizations derive stem
cells from a range of pre-cursor and non-cardiac tissues and then attempt to
differentiate those cells to become and support heart tissue, Capricor’s work
begins and ends with the heart.
Phase II of Capricor’s ALLSTAR clinical trial is funded in part through the
support of the California Institute for Regenerative Medicine.
Director of Investor Relations and Strategy
Press spacebar to pause and continue. Press esc to stop.